The news release highlights a new clinical trial using a twice daily lotion containing what we’re told is “good bacteria” used to fight “bad bacteria” in order to restore the “natural microbial balance” of patients with eczema, or atopic dermatitis.
The premise of this research is that introducing “good bacteria” might decrease the population of Staphlococcus aureus — a bacterium that’s part of the normal flora of our skin and respiratory tract, and speculated to play a role in making eczema worse.
But as with many treatments based on the microbiome, the benefits are touted with language that — although it sounds reasonable and appealing — is not backed by existing research. In fact, here there is no research. The sponsors are still recruiting volunteers for the trial. That should have been made more clear.
The news release does explain why a less toxic alternative might have advantages over existing therapies such as antibiotics and corticosteroids.
Eczema is a very common skin disorder that is notoriously difficult to treat. Finding an effective and non-toxic treatment alternative would be a boon to both patients and those who might develop such a treatment.
But it’s important to note that the cause of eczema is unknown; it’s thought to be triggered by a combination of genetic and environmental factors. That’s why treatment is focused on minimizing possible triggers and symptoms. It’s also a disease that can repeatedly flare up and significantly compromise people’s quality of life.
A non-toxic therapy — as this approach promises to be — could have a major impact on the lives of these people, some of whom are quite incapacitated by this disease. Promising them a long-term solution based on very preliminary, unpublished results is unwarranted. It is very unlikely that one approach, such as altering the microbiome, will yield results for a majority of eczema sufferers.
This lotion is still in clinical trials. Pricing is most likely unavailable.
We’re told the lotion contains “beneficial bacteria to fight harmful bacteria,” and the lead investigator is quoted as saying that this will “help the skin gain back it’s natural balance and create that barrier needed to keep it healthy.”
But we’re given no data from the trials to support this. We’re also not given any context regarding what good bacteria, natural balance, or “that barrier” are.
The only example of a “bad” bacteria mentioned is Staphylococcus aureus. The news release informs us that Staph. aureus makes eczema worse. Previous studies have shown that high levels of Staph. aureus do correlate with increasing severity of eczema.
The lead investigator suggests that applying the lotion twice a day will “eliminate all staph aureus.” But there’s no evidence included to show that this lotion actually improves the eczema.
It should have been acknowledged that staph aureas colonization might be associated with eczema severity and not a cause of it. For example, if people with more severe eczema scratch more, they are more likely to colonize themselves with bacteria they pick up in the environment around them. This does not indicate that reducing the staph will result in improvement of the underlying disorder.
No potential harms from using the lotion are mentioned.
Could there be allergic reactions? If the lotion does, indeed, reduce the amount of Staph. aureus on the skin, are there consequences to that? Or consequences to changing the skin’s microbial balance in general?
Also, many eczema patients are acutely aware that their skin is not just fragile, but also may have open sores; should a bacterial lotion be applied to broken skin? And does this put them at risk of a bacterial infection that can spread?
It’s mentioned that “there is more research to be done” but it’s unclear whether any people have thus far been tested. The release also alludes to a future safety trial and a larger study “to see if the benefits of bacterial cream can truly provide a permanent solution for eczema patients.” This is a far cry from the claims that this cream “restores the natural balance of healthy skin,” and has the potential to be “a long-term solution.”
There’s no indication that any preliminary results have been peer-reviewed, published, or presented at medical conferences. We’re only given the anecdote of one woman, but nothing about her response to the treatment.
The news release is clearly jumping to describing a new treatment that sounds beneficial without any evidence at all.
No disease mongering. Atopic dermatitis is very common and difficult to treat.
Funding sources for this clinical trial are not mentioned. Potential conflicts of interest are also not addressed and this could be relevant since a quick check of the lead author on Dollars for Docs reveals multiple sources of industry funding in the past.
The article does well in mentioning two alternative treatments for eczema that can often prove problematic: antibiotics and corticosteroids.
There are a host of other treatment options as listed here.
The release suggests the benefit of the cream was already proven and hints that the treatment would be available soon.
It would have been helpful to note for readers something like, “because this lotion is in clinical trials, it is not currently available on the market; furthermore the preliminary results have not been published or peer-reviewed.”
There are a number of probiotic creams for sale, according to a quick search of Amazon. What is different about the one being tested?
The release doesn’t rely on sensational terms so we’ll give it a Satisfactory.
The unwarranted claims, such as alluding to a possible “long-term solution” for eczema without providing any evidence, are addressed under other criteria.
Systematic, Criteria-Driven
Puleeeeease... this 'game changer' weight loss drug causes more nausea and vomiting than a placebo. Some game, some change. My friend Gary would spank you for using the eighth word medical reporters should never, ever use. @garyschwitzer @thackerpd
https://www.healthnewsreview.org/toolkit/just-journalists-writing-tips-case-studies/7-words-and-more-you-shouldnt-use-in-medical-news/ https://twitter.com/OttawaCitizen/status/1361426796126830597
A scary @statnews Op-Ed warns that govt attempts to rein in Pharma may cut off access to "life-changing" drugs.
It takes @garyschwitzer to let us know: the author spent 10 years as Pfizer's public-policy chief. https://twitter.com/garyschwitzer/status/1360325022578053123
.@TranspariMED criticizes STAT op-ed for not disclosing pharma funding of author’s institute - similar to criticism we’ve made of STAT op-eds in the past. @transparify @ThinkTankWatch @icer_review https://www.healthnewsreview.org/2021/02/transparency-watchdog-criticizes-stats-non-disclosure-on-pro-pharma-op-ed/
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like